Literature DB >> 26341986

Switching to nintedanib after discontinuation of pirfenidone due to adverse events in IPF.

Katrin Milger1, Nikolaus Kneidinger2, Claus Neurohr2, Frank Reichenberger3, Jürgen Behr4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26341986     DOI： 10.1183/13993003.00584-2015

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  6 in total

1.  Nintedanib Treatment for Idiopathic Pulmonary Fibrosis Patients Who Have Been Switched from Pirfenidone Therapy: A Retrospective Case Series Study.

Authors:  Andrea Vianello; Francesco Salton; Beatrice Molena; Cristian Turato; Maria Laura Graziani; Fausto Braccioni; Valeria Frassani; Dino Sella; Paolo Pretto; Luciana Paladini; Andi Sukthi; Marco Confalonieri
Journal:  J Clin Med       Date:  2020-02-04       Impact factor: 4.241

2.  Baseline characteristics and survival of patients of idiopathic pulmonary fibrosis: a longitudinal analysis of the Swedish IPF Registry.

Authors:  Jing Gao; Dimitrios Kalafatis; Lisa Carlson; Ida H A Pesonen; Chuan-Xing Li; Åsa Wheelock; Jesper M Magnusson; C Magnus Sköld
Journal:  Respir Res       Date:  2021-02-05

3.  Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis.

Authors:  Siri T Lehtonen; Anniina Veijola; Henna Karvonen; Elisa Lappi-Blanco; Raija Sormunen; Saara Korpela; Ulrika Zagai; Magnus C Sköld; Riitta Kaarteenaho
Journal:  Respir Res       Date:  2016-02-04

Review 4.  Role of pirfenidone in the management of pulmonary fibrosis.

Authors:  Keith C Meyer; Catherine A Decker
Journal:  Ther Clin Risk Manag       Date:  2017-04-03       Impact factor: 2.423

Review 5.  Idiopathic pulmonary fibrosis: pathogenesis and management.

Authors:  Giacomo Sgalla; Bruno Iovene; Mariarosaria Calvello; Margherita Ori; Francesco Varone; Luca Richeldi
Journal:  Respir Res       Date:  2018-02-22

Review 6.  Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme.

Authors:  Claudia Valenzuela; Sebastiano Emanuele Torrisi; Nicolas Kahn; Manuel Quaresma; Susanne Stowasser; Michael Kreuter
Journal:  Respir Res       Date:  2020-01-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.